Clinical Trial Update: Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing erythropoietin therapy to induce regulatory T cells in liver transplant recipients with rejection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Transplant Rejection

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: Northwestern University | Conditions: Liver Transplant Rejection | Phase 4 | Status: ACTIVE_NOT_RECRUITING